Gilead Sciences

Gilead Sciences Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Gilead Sciences key operating metrics including Countries, environmental, and social and governance score (ESG).

Countries

FY, 2021

Products

5.0%

FY, 2021

Phase II Trials Products (Viral Diseases)

66.7%

FY, 2021

Operating Metrics

Metrics	FY, 2019	FY, 2020	FY, 2021
Countries	35	35	35
Products	24	20	21
Phase II Trials Products (Viral Diseases)	2	3	1
Phase I Trials Products (Viral Diseases)	3
Phase III Trials Products (Inflammatory and Fibrotic Diseases)	3	2	2
Phase II Trials Products (Inflammatory and Fibrotic Diseases)	7
Phase I Trials Products (Inflammatory and Fibrotic Diseases)	4
Phase III Trials Products (Oncology)	1	3	4
Phase II Trials Products (Oncology)	2	3	1
Phase I Trials Products (Oncology)	7
Clinical Trials	104
Phase III Trials Products	27	8	9
Phase III Trial Products (Viral Diseases)		3	3

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub